Q-omics provides the consensus-scored NGRN profile across patient tissues and cancer cell-line models. NGRN expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, NGRN is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, NGRN RNA expression shows 20,529 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight CESC, HNSC, and ACC as cancer lineages where NGRN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NGRN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NGRN survival associations across molecular data types. NGRN RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NGRN RNA expression–survival associations across cancer types. High NGRN expression shows unfavorable associations in CESC, ACC and UVM, but favorable associations in OV, BRCA and KIRC. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for NGRN RNA expression.
This table summarizes NGRN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NGRN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NGRN shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, LIHC, CHOL and LUSC. The HNSC box plot shows higher NGRN RNA expression in tumor versus normal tissue (log2 FC = +0.720, t-test p < 0.001).
This table shows molecular features associated with NGRN in patient tissues and cancer cell lines. In patient samples, NGRN shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, NGRN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
